ReviewInnovation (Cambridge (Mass.))2026
Dilating the aging clock with light.
Review in Innovation (Cambridge (Mass.)), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precise and rapid modeling of aging remains a significant challenge. This review explores the potential of emerging light-based technologies-including direct light exposure, photodynamic therapy (PDT), and optogenetics-as accelerated, mechanistically targeted models for interrogating aging processes. Unlike conventional methods that rely on chronologically aged organisms or non-specific stressors, these light-driven approaches can induce specific hallmark aging phenotypes within days. This offers unprecedented temporal and spatial control, allowing researchers to precisely trigger and define molecular pathways, such as localized oxidative bursts or programmed protein interactions. Such capabilities provide a powerful platform for testing causal hypotheses about aging, especially organ-specific aging. The review also outlines a framework connecting each light modality to aging, including cellular senescence, telomere attrition, proteostasis loss, and epigenetic drift. It discusses a mechanistic matrix linking each light modality to specific molecular targets and age-associated outcomes. Light-based platforms, when combined with genetic and pharmacological tools, are poised to accelerate discovery in aging by enabling high-throughput and organelle-specific perturbation of aging biology. These approaches could ultimately redefine how we experimentally dissect and potentially modulate the aging process either by rapidly recapitulating aging features for study or by revealing leverage points to slow aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.